



Drug Name: Toujeo (insulin glargine)
 Date: 9-2017

| | |
|-------------------------------|--|
| Drug Name: | Toujeo (insulin glargine) |
| Prescriber Restrictions: | |
| Age Restrictions: | |
| Exclusion Criteria: | |
| Required Medical Information: | <ul style="list-style-type: none"> • Trial and failure of Lantus 100 U/ml due to serious side effects (such as hypoglycemia, injection site reactions due to volume, etc.), or inability to control glucose levels with Lantus. <ul style="list-style-type: none"> ○ HbA1c must be provided ○ Adherence will be checked via pharmacy claims ○ Description of side effect must be provided • Patients is on a high dose of insulin glargine (>160 U/d), i.e. multiple doses required |
| Coverage duration: | 12 months |